News

The trial, which evaluated the safety and efficacy of brodalumab given at two doses every two weeks through subcutaneous injection compared with Stelara and placebo in these patients,

In March 2014, the company had submitted NDA for LBH589 to the FDA, and in May the agency granted priority review status to the compound, reducing the standard

The decision to terminate the trials is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found an increase in the number of

Protopic Ointment (tacrolimus) is indicated to treat moderate to severe eczema. Brand sales were approximately $176 million over the last 52 weeks according to Symphony Health Solutions. Perrigo’s

In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later

The composition of the Diabetes Consortium has evolved over many months. In addition to key personnel from Nuvilex, it consists of principals from Austrianova – Prof. Dr. Walter

To date, CAR-T therapies have shown promise in early human clinical trials for the treatment of blood cancers and allogeneic CAR-Ts have the potential for use as off-the-shelf

rVSV-EBOV was originally developed by the Public Health Agency of Canada (PHAC) and is currently being evaluated in Phase I clinical trials. Merck Vaccines president Dr Julie Gerberding

The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nation’s largest institutional pharmacy and